Patient agreement to systemic anti-cancer

(add name of regimen/protocol)	Patient's first name(s):		
	Date of birth:		
Hospital Name/stamp:	NHS number:		
Responsible consultant:			
Name:			
Job title: Consultant Haematologist			
(include brief explanation if medical term not clear. Include regispecify the indication, route, schedule of administration, and location are provided in the indication for treatment (i.e. tumour site): [Indication for treatment (i.e. tumour site):	ocation of treatment.)		
Route(s) of administration: ☐ Intravenous ☑ Subcutaneous ☑ Oral ☐ O	other:		
Frequency (treatment days and length of cycle): Cycles 1-	8 each is 21 days: Velcade D1, D8 and D15,		
Dexamethasone D1,2,8,9,15,16. Daratumuma	<u> </u>		
for cycles 4-8. For cycles 9-10: 28 day cycles w			
Duration of treatment (number of cycles): Ongoing until	intolerance or disease progression		
\square A separate consent form must be completed	for radiotherapy		
Participation in a clinical trial (trial name): Not applic	able		
Where the treatment will be given: ☐ Outpatient ☐ Day unit/case ☐ Inpatient ☐	Other		

Patient details

Patient's surname/family name:

Statement of health professional

(to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in the hospital /Trust/NHS board's consent policy

Patient identifier/label

			· · · · · · · · · · · · · · · · · · ·				
	Tick all relevant boxes						
	I confirm the patient has capacity	_					
	eve explained the course of treatm	ent	and intended benefit to the patien	it.			
Th	e intended benefits						
	Curative – to give you the best po		•		P.		
	Disease control/palliative – the air The aim is to improve both quality			(the	disease.		
	Adjuvant – therapy given after surgery to reduce the risk of the cancer coming back.						
	Neo-adjuvant – therapy given beforeduce the risk of the cancer compared to the cancer can be cancer ca		• • •	canc	er, allow radical treatment and		
Sig	gnificant, unavoidable or frequ			that	apply):		
\checkmark	Tiredness and feeling weak (fatigue)		Chemotherapy may leak outside of the vein while	\checkmark	Cancer can increase your risk of developing a blood		
i k i i i i i i i i i i i i i i i i i i	An increased risk of getting an infection from a drop in white blood cells – it is harder to fight infections and you can become very ill.		it is being given; this is called extravasation. If this happens when you're having chemotherapy it can damage the tissue around the vein. Tell the nurse straight away if you	abla	clot (thrombosis), and having treatment with anti-cancer medicines may increase this risk further. A blood clot may cause pain, redness and swelling in a leg, or breathlessness and chest pain – you must tell your docto straight away if you have any of these symptoms. Some anti-cancer medicines can damage women's ovaries and men's sperm. This may lead to infertility in men and women and/or early menopause in		
	If you have a severe infection this can be life threatening. Contact your doctor or hospital straight away if:		have any stinging, pain, redness or swelling around the vein. Extravasation is not common but if it happens it's important that it's dealt with quickly. Inflammation of the hands and feet.				
	• your temperature goes over 37.5°C or over 38°C, depending on the advice given by your chemotherapy team	☐ In					
	 you suddenly feel unwell (even with a normal temperature) 		or feet. Impaired hearing or ringing in the ears.		women. Early menopause symptoms include hot flushes, vaginal dryness.		
\checkmark	Anaemia (low number of red	\checkmark	Problems with the eyes.	\checkmark	Some anti-cancer medicines may damage the development		
	blood cells).	\checkmark	Allergic reactions.		of a baby in the womb. It is		
\checkmark	Bruising or bleeding.	\checkmark	Impaired heart function.		important not to become pregnant or father a child while you are having treatment and for a few months afterwards. It is important to use effective contraception during and for		
\checkmark	Feeling sick (nausea) or being sick (vomiting).	abla	Impaired lung function.				
\checkmark	Sore mouth and ulcers.		Impaired kidney function.				
\checkmark	Diarrhoea.		Impaired liver function.				
\checkmark	Constipation.		Fluid retention.		several months after treatment. You can talk to your doctor or		
\checkmark	Taste changes.		Tumour lysis syndrome.	abla	nurse about this.		
\checkmark	Loss of appetite.		Problems with sleep.		Complications of treatment can very occasionally be life threatening and may result in death. The risks are different for every individual. Potentially life threatening complications include those listed on this form, but, other exceedingly rare side effects may also be life threatening.		
\checkmark	Hair loss.	\checkmark	Flu-like symptoms.				
\overline{V}	Skin rashes.	\checkmark	Unstable blood sugars.				
	Nail changes.	\checkmark	Risk of a second cancer.				
V	vait criariges.	\checkmark	Potential side-effects with the anti-sickness medication may include: constipation, headaches, indigestion, difficulty sleeping and agitation.				

Statement of health professional (continued)

D = 11 = 1	
Patient identifier/label	
1 additional additiona	

Other risks and information:	
Velcade: peripheral neuropathy, ileus, dizziness, di	arrhoea, nausea
Daratumumab: interference with blood compatabilit	y testing, infusion reactions (11%), hepatitis B reactivation
Dexamethasone: fluid retention, mood changes, ref	flux, insomnia, muscle weakness, increased sugars
 I have discussed the intended benefits of the treat treatments (including no treatment). I have discussed the side effects of the treatment a in the future, and that there may be some side effects reported. Each patient may experience side effects. I have discussed what the treatment is likely to invite treatment, blood and any additional tests, following the treatment in the patient, that he/she has the contact the responsible consultant or team if they have discussed concerns of particular importance (please write details here): 	ment advised and risks of any available alternative advised, which could affect the patient straight away or ects not listed because they are rare or have not yet been stifferently. Folve (including inpatient / outpatient treatment, timing of ow-up appointments etc) and location. The right to stop this treatment at any time and should wish to do so. The to the patient in regard to treatment
Clinical management guideline/Protocol comp Yes No Not available If No please document reason here:	
The following leaflet has been provided:	Healthcare professional details:
✓ Information leaflets for: DVd	Signed:
 ✓ 24 hour alert card or SACT advice service contact details ☐ SACT record booklet / diary ☐ Other, please state: 	Date: Name (print): Job title:
Statement of interpreter (where appro- Interpreter booking reference (if applicable):	ppriate)
I have interpreted the information above to the patient they can understand.	to the best of my ability and in a way in which I believe
Signed:	Date:
Name (print):	
Job title:	

Statement of patient

Patient identifier/label

planned in advance, you should already have your own the proposed treatment. If not, you will be offered a copy ere to help you. You have the right to change your mind at
ake a decision about treatment.
n.
but has indicated their consent. Young people/children may
Date:
Date:
Further information for patients Contact details (if patient wishes to discuss options later): Contact your hospital team if you have any questions about cancer and its treatment. Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone 0808 800 4040, Monday to Friday, 9am to 5pm. Alternatively visit www.cruk.org for more information. These forms have been produced by Guy's and St. Thomas' NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT. The project is supported by Cancer Research UK. This does not mean you are taking
k

Guidance for health professionals

(to be read in conjunction with the hospital's consent policy)

What a consent form is for

This form documents the patient's agreement to go ahead with the treatment you have proposed. It is not a legal waiver – if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a check-list of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient.

The law on consent

See the following publications for a comprehensive summary of the law on consent. Consent: Patients and doctors making decisions together, GMC 2008 (available at www.gmc-uk.org/guidance), and Reference guide to consent for examination or treatment, Department of Health, 2nd edition 2009 (available at www.doh.gov.uk).

Who can give consent

Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has "sufficient understanding and intelligence to enable him or her to understand fully what is proposed", then the child will have capacity to give consent for himself or herself.

Young people aged 16 and 17, and younger children with capacity, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent, someone with parental responsibility may do so on their behalf and a separate form is available for this purpose. Even where children are able to give consent for themselves, you should always involve those with parental responsibility in the child's care, unless the child specifically asks you not to do so. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that the patient has given consent orally or non-verbally.

When NOT to use this form

If the patient is 18 or over and lacks the capacity to give consent, you should use an alternative form (form for adults who lack the capacity to consent to investigation or treatment). A patient lacks capacity if they have an

Patient identifier/label

impairment or disturbance of the brain, affecting the way their mind works. For example, if they cannot do one of the following:

- understand information about the decision to be made
- retain that information in their mind
- use or weigh this information as a part of their decision making process, or
- communicate their decision (by talking, using sign language or any other means)

You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so.

Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy.

Information

Information about what the treatment will involve. its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'significant, unavoidable or frequently occurring' risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient's notes.

References

- 1. Summary of Product Characteristics (SmPCs) for individual drugs: https://www.medicines.org.uk/emc
- Cancer Research UK: https://www.cancerresearchuk.org/aboutcancer/cancer-in-general/treatment/cancer-drugs
- Macmillan Cancer Support: https://www.macmillan.org.uk/ information-and-support/treating/chemotherapy/drugs-andcombination-regimens
- 4. Guy's and St. Thomas' NHS Foundation Trust, Chemotherapy consent forms.